About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNANCT00422006

Study of the Role of PCSK9 and FXR in the Physiopathology of the Joint Dyslipidemia Associated to the Human Immunoresistance

Experimental results are strongly suggesting that PCSK9 and FXR could occur in the physiopathology of human joined dyslipidemia. But no data in the literature can validate the potential role of these ...

Lead sponsor: Nantes University Hospital•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Nantes University Hospital

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•corporal mass index \> 40 kg/m² or \> 35 kg/m² associated to a co-morbidity resistant to a diet
•bariatric surgery planned
•no lipid-lowering drugs during 4 weeks before surgery
•no treatment by metformin during 4 weeks before surgery
•no treatment by glitazones during 8 weeks before surgery
•age of the patient between 18 and 65 years
•consent form signed
•patient with social insurance

Exclusion Criteria

•age inferior to 18 years
•women pregnant
•coagulation troubles
•surgery contraindicated
•Chronic hepatitis B or C active
•VIH infected
•other chronic hepatic disease
•patient with dyslipidemia under lipid-lowering drugs in secondary prevention of a cardiovascular pathology
•Type 2 diabetes under insulinosensitivator treatments

Related studies

Five PLus Year EffIcacy of Endoscopic Sleeve Gastroplasty (ESG) for Sustained WeigHT Loss

NCT06894498 · Obesity and Obesity-related Medical Conditions, Weight Loss

Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes

NCT05124808 · Gestational Diabetes, Pregnancy, High Risk, and more

RECRUITINGPhase 3

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086 · Ulcerative Colitis, Obesity or Overweight

RECRUITINGPhase 3

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

NCT07595549 · Obesity, Overweight and/or Obesity, and more

RECRUITINGPhase 3

Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

NCT07284875 · Obesity, Overweight

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 3, 2014Terms

Trial snapshot

StatusCOMPLETED

PhaseNA

Enrollment111

Start dateFeb 2008

Last updatedApr 3, 2014

Condition

Locations shown

CHU de Nantes

Nantes

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 3, 2014Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions